Oxaliplatin Injection, Solution
Product Images NDC 72603-301

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 72603-301). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Nor0i 0001 01

Chemical structure of Oxaliplatin, showing a platinum (Pt) atom coordinated with a cyclohexane ring containing two amine (NH2) groups and two oxalate groups (O-C=O). The diagram illustrates the molecular connectivity typical for this platinum-based chemotherapy agent.*

FDA Label Image

Nor0i 0001 02

A Kaplan-Meier survival curve chart showing disease progression-free survival (PFS) probability over time in months for two treatment arms labeled POLPOX4 and LV5FU2. The chart includes a legend detailing the number and percentage of events per arm, a hazard ratio with confidence interval, a stratified logrank test p-value, and a table showing the number of patients at risk at various time points.*

FDA Label Image

Nor0i 0001 03

A Kaplan-Meier survival curve chart depicting disease-free survival (DFS) probability over time in months, comparing different treatment arms in Stage III patients. The graph includes a hazard ratio with confidence interval and a p-value from a logrank test.*

FDA Label Image

Nor0i 0001 04

A Kaplan-Meier survival curve graph showing the percentage of patients surviving over 24 months for three treatment groups: Oxaliplatin plus 5-FU/LV, Oxaliplatin plus Irinotecan, and Irinotecan plus 5-FU/LV. Survival percentages decline over time, with median survival times noted for each group. The graph includes a p-value indicating statistical significance for comparison.*

FDA Label Image

Nor0i 0001 05

Label for Oxaliplatin Injection, USP, 50 mg per 10 mL (5 mg/mL) sterile aqueous solution for intravenous use. It is a 10 mL single-dose vial marked as a cytotoxic agent. The label includes storage instructions and manufacturer information for NorthStar Rx LLC and Gland Pharma Limited, India. The label also contains warnings against mixing with sodium chloride solutions.*

FDA Label Image

Nor0i 0001 06

Oxaliplatin Injection, USP 50 mg per 10 mL (5 mg per mL) carton labeling for intravenous use. The sterile aqueous solution is preservative-free and supplied in a 10 mL single-dose vial. The product is labeled as a cytotoxic agent and manufactured for NorthStar Rx LLC with manufacturing by Gland Pharma Limited, India. Storage and handling instructions are included on the packaging.*

FDA Label Image

Nor0i 0001 07

Label for Oxaliplatin Injection, USP 100 mg per 20 mL (5 mg/mL) sterile aqueous solution for intravenous use. The single-dose vial contains oxaliplatin with water for injection, indicated as a cytotoxic agent. Manufactured by Gland Pharma Limited for NorthStar Rx LLC. Includes storage and administration instructions.*

FDA Label Image

Nor0i 0001 08

Packaging label for Oxaliplatin Injection, USP 100 mg per 20 mL (5 mg per mL) intravenous solution. The label states it is for intravenous use only, cytotoxic, preservative-free, in a single-dose vial. Manufactured for NorthStar Rx LLC and produced by Gland Pharma Limited, India. The label includes storage instructions, a barcode, and mentions it should not be mixed with sodium chloride-containing solutions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.